Targeted treatment of metastatic ALK‐rearranged non‐small cell lung cancer with ALK inhibitors leads to higher response rates and improves progression‐free survival (PFS) relative to conventional chemotherapy regimens.6 The gene discussed is ALK; the disease is lung cancer.